This review focuses on tapentadol sustained release and summarises data from clinical studies that investigated the impact of tapentadol SR on functionality and HR-QoL in patients with severe CNCP.
It also provides commentary from Associate Professor Marc Russo, a specialist Pain Medicine Physician in Newcastle, Australia whose focus is on cutting edge treatments to advance the field of pain medicine and research into CRPS. He is the past Secretary of the International Neuromodulation Society, Examiner for Faculty of Pain Medicine and Honorary Associate Professor, University of Hong Kong.
Please login below to download this issue (PDF)